HER3 Trials in NSCLC
Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Released: December 26, 2023

Rebecca S. Heist
Rebecca S. Heist, MD, MPH
Helena Yu
Helena Yu, MD

Activity

Progress
1
Course Completed

This second episode in a 3-part series on HER3-targeted agents in NSCLC covers current clinical trials with HER3-targeted therapy, including:

  • Recent data on patritumab deruxtecan (HER3-DXd) in the HERTHENA-Lung01 trial
  • The EGFRxHER3 bispecific antibodies BL-B01D1 and izalontamab
  • The HER2xHER3 bispecific antibody zenocutuzumab
  • The HER3-targeted antibody–drug conjugate SHR-A2009